VRTX
Vertex Pharmaceuticals Incorporated · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +4.0% ·
share flow -4.1% ·
net new positions 0.0%
· formula
Ownership fragmentation: more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 1.30M | $664.72M | n/a | n/a |
| Q2 2026 | 175 | -1 | 212.01M | $105.17B | +5 | −5 |
| Q1 2026 | 178 | 0 | 208.95M | $93.29B | +5 | −6 |
| Q4 2025 | 177 | -1 | 219.78M | $99.62B | +2 | −2 |
| Q3 2025 | 26 | +1 | 120.93M | $47.35B | +1 | −1 |
| Q2 2025 | 23 | +1 | 112.15M | $49.92B | +3 | −2 |
| Q1 2025 | 19 | -2 | 60.41M | $29.28B | n/a | −2 |
| Q4 2024 | 21 | +1 | 60.08M | $24.19B | +1 | n/a |
| Q3 2024 | 19 | 0 | 46.24M | $21.49B | n/a | n/a |
| Q2 2024 | 19 | n/a | 46.47M | $21.77B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Capital World Investors ✦ | 25.91M | -9.8% | $10.15B | 1.4% | ▼ Trim | 6 | SEC ↗ |
| 2 | The Vanguard Group ✦ (passive) | 24.22M | +1.0% | $9.48B | 0.1% | ▲ Add | 2 | SEC ↗ ×7 |
| 3 | BlackRock ✦ (passive) | 22.25M | +1.7% | $8.72B | 0.2% | ▲ Add | 2 | SEC ↗ ×22 |
| 4 | JPMorgan Chase ✦ | 12.87M | n/a | $5.04B | 0.2% | n/c | 1 | SEC ↗ ×44 |
| 5 | State Street Global Advisors ✦ (passive) | 11.61M | -1.4% | $4.55B | 0.2% | ▼ Trim | 4 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 5.97M | +0.8% | $2.33B | 0.1% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | Wellington Management ✦ | 4.77M | -0.9% | $1.87B | 0.3% | ▼ Trim | 6 | SEC ↗ ×8 |
| 8 | Fidelity (FMR) ✦ | 3.30M | -48.4% | $1.29B | 0.1% | ▼ Trim | 2 | SEC ↗ ×5 |
| 9 | Morgan Stanley ✦ | 3.11M | n/a | $1.22B | 0.1% | n/c | 1 | SEC ↗ ×21 |
| 10 | T. Rowe Price ✦ | 3.04M | -3.7% | $1.19B | 0.1% | ▼ Trim | 6 | SEC ↗ ×2 |
| 11 | Goldman Sachs Group ✦ | 1.48M | n/a | $581.45M | 0.1% | n/c | 1 | SEC ↗ ×5 |
| 12 | Renaissance Technologies ✦ | 735.89K | -26.8% | $288.20M | 0.4% | ▼ Trim | 6 | SEC ↗ |
| 13 | Adage Capital Partners ✦ | 482.50K | +170.8% | $188.96M | 0.3% | ▲ Add | 6 | SEC ↗ |
| 14 | Arrowstreet Capital ✦ | 381.19K | +520.1% | $149.29M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 15 | Baillie Gifford ✦ | 207.06K | -2.5% | $81.09M | 0.1% | ▼ Trim | 6 | SEC ↗ ×4 |
| 16 | Citadel Advisors ✦ | 173.50K | +501.9% | $67.95M | 0.1% | ▲ Add | 6 | SEC ↗ ×2 |
| 17 | AQR Capital Management ✦ | 161.68K | +14.2% | $63.32M | 0.0% | ▲ Add | 6 | SEC ↗ ×5 |
| 18 | Marshall Wace ✦ | 45.88K | -60.8% | $17.97M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 19 | Millennium Management ✦ | 41.04K | New | $16.07M | 0.0% | New | 1 | SEC ↗ |
| 20 | Tweedy, Browne ✦ | 39.06K | +4.9% | $15.30M | 1.3% | ▲ Add | 6 | SEC ↗ |
| 21 | Bridgewater Associates ✦ | 38.32K | +11.4% | $15.01M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 22 | Fisher Asset Management ✦ | 25.96K | +0.8% | $10.17M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 23 | ARK Investment Management ✦ | 25.66K | +6.7% | $10.05M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 24 | Gotham Asset Management ✦ | 21.89K | +2.5% | $8.57M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 25 | D. E. Shaw & Co. ✦ | 3.34K | -83.3% | $1.31M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 26 | GAMCO Investors ✦ | 512 | 0.0% | $200,520 | 0.0% | Held | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Millennium Management | $16.07M | 0.0% |
Exited
| Norges Bank | $1.59B | was 0.2% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1,678 holders, 225.07M shares, $98.10B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.